As part of a bid to consolidate its footprint in Massachusetts, Biogen is foregoing its old home base to put down new roots in Cambridge. That said, the company won’t be moving far from its ...

Cambridge-based biotech Biogen Idec, the maker of the multiple sclerosis drug Tysabri, linkurl:announced;http://investor.biogenidec.com/phoenix.zhtml?c=148682&p=irol ...

With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three buildings to one.

Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...

Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint; New ...